

Hedged Global Growth Share Fund

Fund Focus - April 2025



Investment Strategy

The fund invests in securities with high growth potential that are primarily listed on international stock exchanges.

The fund aims to be fully hedged at all times providing investors with exposure to underlying share price movements but minimising the effect of foreign exchange movements.

Portfolio Characteristics

Funds Under Manageme..	\$147.98m
Number of Holdings	107
Turnover Ratio %	54.22
Latest Distribution Date	30 June 2024
Latest Distribution Amount	0.0719
Benchmark	MSCI World (ex-Australia) Accumulation Index (fully hedged into\$A) (net dividends reinvested)

Fund Facts

APIR Code	ZUR0621AU
Inception Date	26 October 2015
Total Est. Management Cost %	0.99
Est. Transactional Op. Cost %	0.1
Buy/Sell Spread %	0.03
Distribution Frequency	Semi Annually
Underlying Fund Manager	American Century Investments

Fund Performance After Fees*


	1 Month	3 Months	1 Year	3 Years	5 Years	Since Inception
Distribution	0.00	0.00	6.20	5.43	10.02	10.02
Growth	0.79	-6.64	2.76	1.84	-0.44	0.49
Total	0.79	-6.64	8.96	7.27	9.57	10.52
Benchmark	-0.45	-6.30	9.83	9.87	12.96	13.70

Market Exposure




Investment Growth (\$10,000)

1 May 2020 to 30 Apr 2025




Risk Reward

1 May 2020 to 30 Apr 2025



Portfolio Equity Sectors (%)



Financials	20.26
Information Technology	20.04
Industrials	13.98
Health Care	13.35
Consumer Discretionary	9.13
Communication Services	6.87
Utilities	6.06
Energy	4.53
Materials	2.53
Real Estate	0.69

Top 10 Holdings (%)

	Weight	Benchmark
Microsoft Corp Commo	5.18	4.14
Nvidia Corp Common S	3.83	3.96
Amazon.Com Inc Commo	3.62	2.59
Meta Platforms Inc C	2.40	1.78
Alphabet Inc Common	2.20	1.38
Mastercard Inc Commo	1.96	0.67
Eli Lilly & Co Commo	1.83	1.08
Abbvie Inc Common St	1.75	0.51
Societe Generale Sa	1.56	0.06
Sap Se Common Stock	1.55	0.45

Risk Statistics

1 May 2020 to 30 Apr 2025

Std Dev	15.80
Alpha	-3.65
Beta	1.06
Sharpe Ratio (arith)	0.61
Up Capture Ratio	0.99
Down Capture Ratio	1.18
Currency Management %	100

Market Commentary

The Trump Administration's early April tariff announcements and subsequent revisions triggered financial market volatility. But market unrest subsided by late April, and US stocks declined only modestly for the month. Inflation in the US continued to moderate, though consumer sentiment sagged. Once again, investors generally favoured non-US stocks, which delivered solid gains for the month. Bonds also posted gains.

The US government's first estimate of first-quarter annualised gross domestic product (GDP) showed the economy slightly contracted, the first decline in three years. A surge in imports was the key culprit, as businesses stockpiled goods ahead of Trump's tariff announcements. Other key GDP components, including investments and consumer spending, increased and offset much of the effects from imports and sagging government spending.

Non-US developed markets stocks advanced in April, outperforming the broad US and emerging markets. The European Central Bank cut all three of its benchmark interest rates as global trade tensions created growing risks to Europe's economic outlook. Meanwhile, UK policymakers held rates steady. In Japan, stocks rallied, while inflation inched lower for the second straight month.

Fund Commentary

The Fund rose in April and outperformed the index return. Calendar year-to-date, the Fund is ahead of the index return.

The key positive contributors included BayCurrent and Societe Generale.

BayCurrent - Shares of this Japan-based information technology consulting business advanced as the company announced its fiscal 2025 earnings results, a new share repurchase program and a dividend increase. The company is benefiting from the government's encouragement of greater digital transformation in the corporate sector.

Societe Generale - The France-based investment bank rose as the company reported strong first-quarter results due to a continued rebound in retail banking and strong equity trading. The bank is benefiting from initiatives to improve profitability and narrow the performance gap versus its European peers.

The key detractors from performance included Fiserv and AbbVie.

Fiserv - The stock price of this payments and financial services technology provider dropped after the company's quarterly financials reflected slowing growth in its Clover point-of-sale operations and a decline in payments processing activity in its merchant solutions segment. Full-year guidance, however, was maintained.

AbbVie. A position in this biopharmaceutical company detracted from relative performance despite the company posting quarterly sales and profits that surpassed estimates. Management also raised its profit guidance for the full year, though it noted a potential impact of tariffs.

Notable purchases in April included Netflix while notable sales included Morgan Stanley and Novo Nordisk.

Netflix - A position was initiated in this online streaming provider after recent strong earnings indicated that new pricing tiers have been effective in retaining and growing subscribers. Growth will be further supported as its advertising business starts to scale, and international audience expands.

Morgan Stanley – The stock was exited as initial expectations around a recovery in investment banking are at risk due to rising economic uncertainties brought about by the potential of a trade war.

Novo Nordisk – The position was exited on rising uncertainty around demand for its GLP-1 drug.

* Performance returns quoted are compound rates of return calculated on exit prices and assume reinvestment of distributions. Returns are calculated net of all ongoing fees and any taxes payable by the fund. Total return includes both growth and distribution returns. Growth return is the change in exit price over the relevant period. The benchmark return shown is a gross return. Please note that figures shown are rounded to one decimal place, therefore some rounding errors may occur.

^ The Estimated Total Management Cost of 0.99% includes an Estimated Performance Fee of 0% and Estimated Indirect Costs of 0.01%.

Past performance is not a reliable indicator of future performance.

This report is issued by Zurich Investment Management Limited ABN: 56 063 278 400, AFSL: 232511, GIIN: FVHHKJ.00012.ME.036 : . The information in the report has been derived from sources reasonably believed to be reliable and accurate and is to be used for research purposes only. Subject to law, none of the companies of the Zurich Financial Services Australia Limited Group, nor their directors or employees, gives any representation or warranty as to the reliability, accuracy or completeness of the information, nor accepts any responsibility arising in any way (including by reason of negligence) from errors in or omissions from, the information provided. A Product Disclosure Statement (PDS) for the Fund is available and can be obtained by calling Zurich Investments on 131 551. The PDS should be considered in deciding whether to acquire, or to continue to hold, an investment in the fund. This information is of a general nature only and does not take into account the investment objectives, financial situation or particular needs of any investor and should not be taken as a securities or stock recommendation. These factors should be considered before any investment decision is made in relation to the fund. Furthermore, this product has been designed to meet certain objectives, financial situations and needs, which are described in our Target Market Determination available at zurich.com.au/tmd PIRD-023125-2025